GOKUL REFOILS AND SOLVENT LIMITED

Regd.Office: State Highway No.41 Nr. Sujanpur Patia, Sidhpur-384151
Corporate Office: "Gokul House", 43, Shreemali Co-operative Housing Society Ltd, Opp. Shikhar Building, Navrangpura, Ahmedabad- 380009
CIN: L15142GJ1992PLC018745 **Website:** www.gokulgroup.com

NOTICE

Pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Meeting of the Board of Directors of **GOKUL REFOILS AND SOLVENT LIMITED** will be held on Tuesday, **10th November, 2020** at the Bahuchar Krupa Bungalow, Road Behind SMS Hospital, Near Tapovan Circle, Ahmedabad,- 382424 interalia to consider and to approve Standalone and Consolidated Unaudited Financial Results and cash flow statement for the Second quarter and half year ended on **30th September, 2020** along with various other businesses. This information is posted on Company's website at **www.gokulgroup.com** and BSE website at **www.bseindia.com** and NSE website at **www.nseindia.com.**

For, Gokul Refoils and Solvent Limited
Sd/-
Place: Ahmedabad **Abhinav Mathur**
Date: 03.11.2020 **Company Secretary**

SHREE RAM PROTEINS LIMITED

CIN:L01405GJ2008PLC054913
Registered Office:Imperial Heights Tower-B, Second Floor, Office No. B-206, 150 Ft Ring Road, Opp Big Bazar Rajkot -360005 Phone: +91-2825-280634/35; Fax: +91-7878036500
Website: www.shreeramproteins.com; Email:info@shreeramproteins.com

NOTICE OF BOARD MEETING

NOTICE is hereby given that, pursuant to Regulation 29 read with Regulation 47 of the SEBI (LODR) Regulations, 2015, the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 11, 2020 at 04:00 PM at the Registered Office of the Company, inter alia to consider, approve & take on record the Unaudited Financial Result of the Company for the quarter ended on September 30, 2020 as per Regulation 33 of the Listing Regulation.

Pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015, afore said notice can be accessed from the Company's Website at www.shreeramproteins.com and can also be accessed from the website of the Stock Exchange i.e. NSE Limited at www.nseindia.com.

For, Shree Ram Proteins Limited
Sd/-
Place: Rajkot **Lalitkumar Chandulal Vasoya**
Date: 04-11-2020 **Chairman & Managing Director DIN-02296254**

Arman Financial Services Limited

Regd. Office: 502-503, Sakar III, Opp. Old High Court, Off Ashram Road, Ahmedabad-380014. Ph.: 079-40507000, 27541989
CIN: L55910GJ1992PLC018623
Email: finance@armanindia.com, Website: www.armanindia.com

NOTICE

Notice is hereby given that pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the meeting of the Board of Directors of the Company will be held on Wednesday, November 11, 2020. inter alia, to consider and approve the Standalone / Consolidated Unaudited Financial Results of the Company for the Quarter / Half Year ended on September 30, 2020.

The details of the aforesaid meeting are available on the website of the Company i.e. www.armanindia.com and website of the stock exchanges i.e. www.bseindia.com and www.nseindia.com.

For Arman Financial Services Limited
Aalok Patel
Joint Managing Director
(DIN: 02482747)

AIRAN LIMITED

Regd. Office : 408, Kirtiman Complex, B/h. Rembrandt, C. G. Road, Ahmedabad-380006, INDIA.
Ph.: +91-79-2646 2233, +91-8866442200 - CIN : L74140GJ1995PLC025519
Email : contact@airanlimited.com, **Website :** www.airanlimited.com, www.airanlimited.in

નોટિસ

સેબી (નિયમનની ફરિયાદો અને જાહેરાત જરૂરિયાતો) રેગ્યુલેશન ૨૦૧૫ના રેગ્યુલેશન ૪૭ સાથે વાંચીને રેગ્યુલેશન ૨૯ મુજબ કંપની દ્વારા નોટીસ આપવામાં આવે છે કે કંપનીના બોર્ડ ઓફ ડિરેક્ટર્સની બેઠક ગુરૂવાર તા. ૧૨મી નવેમ્બર, ૨૦૨૦ના રોજ યોજવાનાર છે. તેમા ૩૦ સપ્ટેમ્બર ૨૦૨૦ના રોજ સમાપ્ત થયેલા કંપનીના ત્રિમાસિક ગાળા અને હાલ્ફયરલી સ્ટેન્ડઅલોન અને કોન્સોલીડેટેડ નાણાંકીય પરિણામોની વિચારણા કરીને તેને બહાલી આપવામાં આવશે.

સેબી (LODR) રેગ્યુલેશન ૪૭, ૨૦૧૫ના અનુસંધાનમાં ઉપરોક્ત નોટીસ કંપનીની વેબસાઇટ www.nseindia.com અને www.airanlimited.com પર મેળવી શકાશે.

વતી, એરન લિમિટેડ
નવેમ્બર ૦૪, ૨૦૨૦ **સ્તુતિ કિનારીવાલા**
સ્થળ : અમદાવાદ **કંપની સેક્રેટરી અને કોમ્પલાઇન્સ ઓફિસર**

શ્રી જગદંબા પોલિમર્સ લિમિટેડ

CIN: L17239GJ1985PLC007829
રજીસ્ટર્ડ ઓફિસ : ૮૦૨, નરનારાયણ કોમ્પ્લેક્ષ, નવરંગપુરા પોસ્ટ ઓફિસ સામે, નવરંગપુરા, અમદાવાદ-૩૮૦૦૦૯, ગુજરાત
ઈમેઈલ આઈડી : admin@jagdambapolymers.com
વેબસાઈટ : www.shrijagdamba.com **ફોન :** 079-26565792

નોટીસ

આથી સૂચિત કરવામાં આવે છે કે સેબી (લિસ્ટીંગ ઓબ્લીગેશન એન્ડ ડિસ્કલોઝર રિક્વાયરમેન્ટ) રેગ્યુલેશન ૨૦૧૫ ના રેગ્યુલેશન ૪૭ અનુસાર **શ્રી જગદંબા પોલીમર્સ લિમિટેડના** બોર્ડ ઓફ ડિરેક્ટર્સની મિટિંગ, **ગુરૂવાર, ૧૨ નવેમ્બર, ૨૦૨૦** ના રોજ કંપનીની રજીસ્ટર્ડ ઓફિસે નીચે દર્શાવેલ બાબતો ધ્યાને લેવા માટે મળશે : **(૧) ૩૦ સપ્ટેમ્બર, ૨૦૨૦**ના રોજ પૂર્ણ થયેલ ત્રિમાસિક તેમજ અર્ધવાર્ષિક અનઓડિટેડ નાણાકીય પરિણામ સહિતના મર્યાદિત સમીક્ષા અહેવાલો **(૨)** કોઈ અન્ય બાબત જે કંપનીના બોર્ડ ઉપર ચેરમેનની મંજૂરીથી રજુ થાય તે ધ્યાને લેવા. આ વિશેની માહિતી કંપનીની વેબસાઈટ **www.shrijagdamba.com** પર તથા સ્ટોક એક્સચેન્જની વેબસાઈટ **www.bseindia.com** પર પણ ઉપલબ્ધ છે.

ટ્રેડીંગ વિન્ડો પરિણામો જાહેર થયા પછીના ૪૮ કલાક સુધી બંધ રહેશે તેની નોંધ લેવા વિનંતી.

શ્રી જગદંબા પોલીમર્સ લિમિટેડ વતી
સહી /-
તા : ૦૩.૧૧.૨૦૨૦ **કુંજલ સોની**
સ્થળ : અમદાવાદ **કંપની સેક્રેટરી**

ગોપાલા પોલિપ્લાસ્ટ લીમીટેડ

(CIN:- L25200GJ1984PLC050560)
Reg. Office: - Plot No. 485, Santej Vadsar Road, Santej, Tal. Kalol, Dist. Gandhinagar-Gujarat - 382721 **Corporate Office:-** H B Jirawala House, 13 Nav Bharat Society, Opp. Panchsheel Bus Stop, Usmanpura, Ahmedabad-13

પબ્લિક નોટીસ

આથી નોટીસ આપવામાં આવે છે કે ઈન્સોલવન્સી એન્ડ બેન્કરપ્સી કોડ (આઈબીસી) ૨૦૧૬ ની કલમ ૩૦ (૬) હેઠળ માનનીય રાષ્ટ્રીય કંપની લો ટ્રિબ્યુનલ, અમદાવાદ બેંચ દ્વારા ૦૭-૦૮-૨૦૨૦ રોજ માન્ય કરવામાં આવેલ ઠરાવ યોજના હેઠળ શેર મૂડી ઘટાડાની અસર આપવા માટે કંપની એકટ ૨૦૧૩ ની કલમ ૬૧ અને સેબી ના (લીસ્ટીંગ ઓબ્લીગેશન એન્ડ ડીસક્લોસર રીકવાયરમેન્ટ રેગ્યુલેશન) ૨૦૧૫ ના નિયમ ૪૭ ને અનુલક્ષીને કંપનીના બોર્ડ ઓફ ડિરેક્ટર્સને બીએસઈ લીમીટેડ સાથે પરામર્શ કરીને ૧૧-૧૧-૨૦૨૦ ને બુધવાર રેકોર્ડ તારીખ નક્કી કરેલ છે.

શેર મૂડી ઘટાડાની વિગતો નીચે મુજબ છે

અ.નં.	વિગતો	વિશેષ નોંધ
૧	પુર્વ પ્રમોટર્સ અને પ્રમોટર જૂથ ની શેર હોલ્ડિંગ	આથી સંપૂર્ણ ૩૦,૧૩,૩૦૯ ઈક્વિટી શેર પ્રત્યેક રૂ. ૧૦ ની મૂળ કીમતના છે તે રદ થઈને શૂન્ય થઈ જશે. આથી સંપૂર્ણ ૪,૮૦,૦૦૦ પ્રેફરેન્સ શેર પ્રત્યેક રૂ. ૧૦૦ ની મૂળ કીમતના છે તે રદ થઈને શૂન્ય થઈ જશે.
૨	જાહેર	પ્રવર્તમાન ૩૨ ઈક્વિટી શેર જે રૂ. ૧૦ ની મૂળ કીમતના છે તેના બદલામાં નવો ૧ ઈક્વિટી શેર જે રૂ. ૧૦ ની મૂળ કીમત નો હશે તે જારી કરવામાં આવશે અને અપૂર્ણાક શેર ઘટીને શૂન્ય થઈ જશે.

તારીખ : ૦૩-૧૧-૨૦૨૦ **ગોપાલા પોલીપ્લાસ્ટ લીમીટેડ વતી**
સ્થળ : અમદાવાદ **ખુશ્બુ સુરાના, (કંપની સચીવ)**

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES AND IS NOT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA

GLAND PHARMA LIMITED

Our Company was incorporated as Gland Pharma Private Limited, a private limited company, at Hyderabad under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the Company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994, and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956. For further details of change in name and registered office of the Company, see *"History and Certain Corporate Matters"* on page 141 of the Red Herring Prospectus dated October 31, 2020 ("**RHP**").

Registered and Corporate Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma 'X' Roads, D.P. Pally, Dundigal, Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India; **Tel:** +91 40 3051 0999
Website: www.glandpharma.com; **Contact Person:** Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer; **E-mail:** investors@glandpharma.com; **Corporate Identity Number:** U24239TG1978PLC002276

OUR PROMOTERS: FOSUN PHARMA INDUSTRIAL PTE. LTD AND SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

INITIAL PUBLIC OFFER OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF GLAND PHARMA LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹12,500 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 34,863,635 EQUITY SHARES, INCLUDING UP TO 19,368,686 EQUITY SHARES BY FOSUN PHARMA INDUSTRIAL PTE. LTD ("PROMOTER SELLING SHAREHOLDER") AND UP TO 10,047,435 EQUITY SHARES BY GLAND CELSUS BIO CHEMICALS PRIVATE LIMITED, UP TO 3,573,014 EQUITY SHARES BY EMPOWER DISCRETIONARY TRUST, AND UP TO 1,874,500 EQUITY SHARES BY NILAY DISCRETIONARY TRUST (COLLECTIVELY, THE "OTHER SELLING SHAREHOLDERS" AND COLLECTIVELY WITH THE PROMOTER SELLING SHAREHOLDER ARE REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH EQUITY SHARES, THE "OFFERED SHARES") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER FOR SALE"). THE OFFER SHALL CONSTITUTE [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

• QIB Portion: Not more than 50% of the Offer • Retail Individual Bidders Portion: Not less than 35% of the Offer • Non-Institutional Bidders Portion: Not less than 15% of the Offer

Price Band: ₹ 1,490 to ₹ 1,500 per Equity Share of face value of ₹ 1 each.
The Floor Price is 1,490 times of the face value and the Cap Price is 1,500 times of the face value of the Equity Shares.
Bids can be made for a minimum of 10 Equity Shares and in multiples of 10 Equity Shares thereafter.

ASBA# | **Simple, Safe, Smart way of Application!!!**

*Applications supported by Block Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For details, check section on ASBA below.

Mandatory in public issues. No cheque will be accepted.

UPI — UNIFIED PAYMENTS INTERFACE

UPI-Now available in ASBA for Retail Individual Bidders ("RIBs") applying through Registered Brokers, DPs and RTAs. Retail Individual Bidders also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors are required to ensure that the bank account used for bidding is linked to their PAN.

• ASBA has to be availed by all the investors except Anchor Investors. UPI may be availed by RIBs. • For details on the ASBA and UPI process, please refer to the details given in ASBA Form and abridged prospectus and also please refer to the section "***Offer Procedure***" beginning on page 296 of the RHP. • The process is also available on the website of Association of Investment Bankers of India ("**AIBI**"), BSE Limited ("**BSE**") and the National Stock Exchange of India Limited ("**NSE**", and together with BSE, the "**Stock Exchanges**") and in the General Information Document. ASBA Forms can be downloaded from the websites of the Stock Exchanges and can be obtained from the list of Banks that is displayed on the website of the SEBI at www.sebi.gov.in. List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. • RIBs Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40) and (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43) respectively, as updated from time to time. ICICI Bank Limited has been appointed as Sponsor Bank for the Offer. For offer related queries, please contact the Book Running Lead Managers ("**BRLMs**") on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at their toll free number 18001201740 and Mail ID: ipo.upi@npci.org.in.

Risks to Investors

1. **The 4 Merchant Bankers associated with the Offer have handled 15 public issues in the past three years out of which 5 issues closed below the issue price on listing date.**
2. **There are no listed peers in India engaged in Issuer's line of business.**
3. **The Price/Earnings ratio based on diluted EPS for Fiscal 2020 for the Issuer at the upper end of the Price Band is 30.07 as compared to the NIFTY 50 index Price/Earnings ratio of 31.43 (as on November 2, 2020).**
4. **Average Cost of Acquisition of Equity Shares for the Selling Shareholders is in the range of Nil to ₹ 605.12 per Equity Share, and the Offer Price at the upper end of the Price Band is ₹ 1,500 per Equity Share.**

BID/ OFFER SCHEDULE

OPENS ON: MONDAY, NOVEMBER 09, 2020*
CLOSES ON: WEDNESDAY, NOVEMBER 11, 2020

**The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/ Offer Opening Date.*

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Selling Shareholders may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to the Designated Intermediaries and the Sponsor Bank.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("**SCRR**") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**") (the "**QIB Portion**") provided that our Company and the Selling Shareholders, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("**Anchor Investor Portion**"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("**ASBA**") process providing details of their respective ASBA accounts and UPI ID (in case of RIBs), if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see *"Offer Procedure"* on page 296 of the RHP.

Bidders/Applicants should ensure that DP ID, PAN and the Client ID and UPI ID (if applicable, in case RIBs) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorized the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the Depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk.

Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects of the Company, please see the section titled *"History and Certain Corporate Matters"* on page 141 of the RHP. The Memorandum of Association of the Company is a material document for inspection in relation to the Offer. For further details, please see the section titled *"Material Contracts and Documents for Inspection"* on page 314 of the RHP.

Liability of the members of the Company: Limited by shares

Amount of share capital of the Company and capital structure: The authorised, issued, subscribed and paid up share capital of the Company as on the date of the RHP is as follows: The authorised share capital of the Company is ₹ 563,000,000 divided in to 500,000,000 Equity Shares of face value ₹ 1 each, 5,100,000 CCPS of face value ₹ 10 each and 1,200,000 RCPS of face value ₹ 10 each The pre-Offer issued, subscribed and paid-up share capital of the Company is ₹ 154,949,490 divided into 154,949,490 Equity Shares of face value of ₹ 1 each. For details, please see the section titled *"Capital Structure"* beginning on page 62 of the RHP.

Names of signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them: The names of the signatories of the Memorandum of Association of our Company are M. Venkatapathi Raju and P.R.K.A. Raju, who subscribed to 1 equity share each respectively of face value of ₹ 100 per equity share as initial subscription.

Listing: The Equity Shares to be Allotted through the RHP are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to their letters dated July 23, 2020 and August 5, 2020, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be BSE. A signed copy of the Red Herring Prospectus has been filed with the RoC and the Prospectus shall be delivered to the RoC in accordance with Sections 26(4) and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the RHP up to the Bid/ Offer Closing Date, see *"Material Contracts and Documents for Inspection"* on page 314 of the RHP.

Disclaimer Clause of the SEBI: Securities and Exchange Board of India ("**SEBI**") only gives its observations on the Draft Red Herring Prospectus and this does not constitute approval of either the Offer or the specified securities. The investors are advised to refer to page 277 of the RHP for the full text of the disclaimer clause of SEBI.

Disclaimer Clause of BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the Red Herring Prospectus has been cleared or approved by BSE Limited nor does it certify the correctness or completeness of any of the contents of the Red Herring Prospectus. The investors are advised to refer to page 281 of the RHP for the full text of the Disclaimer clause of the BSE Limited.

Disclaimer Clause of NSE : It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 281 of the RHP for the full text of the disclaimer clause of NSE.

General Risks: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to *'Risk Factors'* on page 21 of the RHP.

BOOK RUNNING LEAD MANAGERS TO THE OFFER				REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
kotak Investment Banking	citi	海通國際 HAITONG	NOMURA	LINK Intime	**Sampath Kumar Pallerlamudi** Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma 'X' Roads, D.P. Pally, Dundigal, Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India **Tel:** +91 40 3051 0999 **E-mail:** investors@glandpharma.com Investors can contact the Company Secretary and Compliance Officer, the BRLMs or the Registrar to the Offer in case of any pre-Offer or post-Offer related problems such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc.
Kotak Mahindra Capital Company Limited 1st Floor, 27 BKC, Plot No. 27, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051 Maharashtra, India **Tel:** +91 22 4336 0000 **E-mail:** glandpharma.ipo@kotak.com **Investor grievance e-mail:** kmccredressal@kotak.com **Website:** www.investmentbank.kotak.com **Contact Person:** Ganesh Rane **SEBI Registration No:** INM000008704	**Citigroup Global Markets India Private Limited** 1202, First International Financial Center, Bandra Kurla Complex, Bandra (East), Mumbai 400 098 Maharashtra, India **Tel:** +91 22 6175 9999 **E-mail:** glandpharma.ipo@citi.com **Investor grievance e-mail:** investors.cgmib@citi.com **Website:** www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm **Contact Person:** Ashish Guneta **SEBI Registration No:** INM000010718	**Haitong Securities India Private Limited** 1203A, Floor 12A, Tower 2A, One Indiabulls Centre, 841, Senapati Bapat Marg, Elphinstone Road Mumbai 400 013, Maharashtra, India **Tel:** +91 22 4315 6857 **E-mail:** gland.pharma.ipo@hitsec.com **Investor grievance e-mail:** India.Compliance@hitsec.com **Website:** http://www.hitsec.com/en-us/haitong-india **Contact Person:** Ritesh Khetan **SEBI Registration No:** INM000012045	**Nomura Financial Advisory and Securities (India) Private Limited** Ceejay House, Level 11 Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai 400 018 Maharashtra, India. **Tel:** +91 22 4037 4037 **E-mail:** glandpharmaipo@nomura.com **Investor grievance e-mail:** investorgrievances-in@nomura.com **Website:** www.nomuraholdings.com/company/group/asia/india/index.html **Contact Person:** Vishal Kanjani / Kshitij Thakur **SEBI Registration No:** INM000011419	**Link Intime India Private Limited** C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg Vikhroli (West), Mumbai 400 083, Maharashtra, India **Tel:** +91 22 4918 6200 **E-mail:** glandpharma.ipo@linkintime.co.in **Investor grievance e-mail:** glandpharma.ipo@linkintime.co.in **Website:** www.linkintime.co.in **Contact Person:** Shanti Gopalkrishnan **SEBI Registration No.:** INR000004058	

AVAILABILITY OF THE RHP: Investors are advised to refer to the RHP and the Risk Factors on page 21 of the RHP, contained therein before applying in the Offer. Full copy of the RHP is available on the website of SEBI at www.sebi.gov.in, website of the BRLMs, i.e., www.investmentbank.kotak.com, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm, www.hitsec.com/en-us/haitong-india and www.nomuraholdings.com/company/group/asia/india/index.html, respectively and on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com, respectively.

AVAILABILITY OF BID CUM APPLICATION FORMS: Bid cum Application Forms can be obtained from the Registered and Corporate Office of **GLAND PHARMA LIMITED, Tel:** +91 40 3051 0999; **BRLMs** : **Kotak Mahindra Capital Company Limited, Tel:** +91 22 4336 0000; **Citigroup Global Markets India Private Limited, Tel:** +91 22 6175 9999; **Haitong Securities India Private Limited, Tel:** +91 22 4315 6857 and **Nomura Financial Advisory and Securities (India) Private Limited, Tel:** +91 22 4037 4037 and **Syndicate Member**: Kotak Securities Limited, Tel: +91 22 6218 5470 at the select locations of the Sub-syndicate Members (as given below), SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. Bid Cum Application Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

Sub-Syndicate Members: Achieivers Equities Limited, Ajcon Global Services Limited, Almondz Global Securities Limited, Amrapali Capital & Finance Services Limited, Anand Rathi Share & Stock Brokers Limited, Axis Capital Limited, Centrum Broking Limited, Edelweiss Broking Limited, Eureka Stock & Share Broking Services Limited, HDFC Securities Limited, ICICI Securities Limited, IDBI Capital Markets & Securities Limited, IIFL Securities Limited, JM Financial Services Limited, Jobanputra Fiscal Services Private Limited, Keynote Capitals Limited, KJMC Capital Market Services Limited, LKP Securities Limited, Motilal Oswal Securities Limited, Prabhudas Lilladher Pvt Limited, Pravin Ratilal Share & Stock Brokers Limited, RR Equity Brokers Private Limited, SAFAL Capital (INDIA) Limited, SBicap Securities Limited, Sharekhan Limited, SMC Global Securities Limited, Systematix Shares & Stocks (India) Limited, Tradebulls Sec Pvt Limited, Way2Wealth Brokers Private Limited and YES Securities (India) Limited

Banker to the Offer/ Escrow Collection Bank/ Refund Bank/ Public Offer Account Bank/ Sponsor Bank : ICICI Bank Limited

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For **GLAND PHARMA LIMITED**
On behalf of the Board of Directors
Sd/-
Company Secretary and Compliance Officer

Place: Hyderabad
Date: November 3, 2020

GLAND PHARMA LIMITED is proposing, subject to, applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the RHP with RoC on October 31, 2020. The RHP is available on the websites of SEBI, BSE and NSE at www.sebi.gov.in, www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs, i.e., www.investmentbank.kotak.com, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm, www.hitsec.com/en-us/haitong-india and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see "*Risk Factors*" beginning on page 21 of the RHP. Potential investors should not rely on the DRHP for making any investment decision.

This announcement is not an offer to sell, or a solicitation of any offer to buy, the Equity Shares in the United States, Canada, Japan, the People's Republic of China or in any other jurisdiction where such an offer or sale would be unlawful. The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act and applicable U.S. state securities laws. There will be no public offering of the Equity Shares in the United States.

Adfactors 418